References

Z
Zeuzem S, Ghalib R, K. Reddy R, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Annals of Internal Medicine. 2015;163(1):1 - 13.
Zeuzem S, Feld J, Wang S. ENDURANCE-1: Efficacy and Safety of 8- versus 12-week Treatment with ABT-493/ABT-530 in patients with Chronic HCV Genotype 1 Infection [Abstract 253]. In: 67th Annual Meeting of the American Association for the Study of Liver diseases, November 11-15. 67th Annual Meeting of the American Association for the Study of Liver diseases, November 11-15.; 2016.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54.
Zuckerman E, Ashkenasi E, Kovaleve Y, et al. The real world Israeli experience of treating chronic hepatitis C genotype 1 patients with advanced fibrosis with Parataprevir/ Ritonavir/ ombitasvir, dasabuvir with or without ribavirin:A large, multi-center cohort. J Hepatology. 2016;64:PS004.
Ø
Øvrehus ALH, Blach S, Christensen PB, et al. Impact of prioritizing treatment in a high resource setting - minimizing the burden of HCV related disease in 15 years. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015:S591.
Top